Drugs / FT836
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07216105 | Nov 2025 → Jan 2028 expected | breast cancer, colorectal cancer, endometrial carcinoma, head and neck squamous cell carcinoma +2 | Fate Therapeutics | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2026-08-13 | Fate Therapeutics | Results Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates fatetherapeutics.com ↗
Preliminary clinical data in SSc presented at the ISSCR 2026 Annual Meeting demonstrate rCRISS25 or greater responses and improvement in mRSS in all four treated patients, with no CRS, ICANS, GvHD, or hypogammaglobulinemia reported |
| 2026-06-01 | Fate Therapeutics | Results Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting fatetherapeutics.com ↗
In this preliminary stage of the study, we are seeing notable tumor reduction in KRASwt metastatic colorectal cancer patients after treatment with FT836, an observation that did not require conditioning chemotherapy with the inclusion of our Sword and Shield™ technology. |
| 2026-05-13 | Fate Therapeutics | Regulatory Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates fatetherapeutics.com ↗
FDA selects FT819 into the CDRP ( CMC Development and Readiness Pilot) program enabling early and enhanced communication with the FDA to ensure CMC readiness for accelerated clinical timelines |
| 2026-05-11 | Fate Therapeutics | Results Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting fatetherapeutics.com ↗
Preclinical data for FT836 shows effective elimination of broad range of cancers in synergy with SOC treatments; radiotherapy and chemotherapy significantly enhance FT836 cytolytic activity and specific trafficking to the tumor site |
| 2026-05-04 | Fate Therapeutics | Results Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases fatetherapeutics.com ↗
CAR T cells Targeting pan-Tumor Antigens MICA/B can be Uniquely Combined with SOC Treatments without Conditioning Chemotherapy for Broad and Effective Therapeutic Application in Cancer |
| 2024-11-08 | Fate Therapeutics | Results Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting fatetherapeutics.com ↗
FT836 Preclinical Data Shows Robust Antigen-mediated Expansion, Functional Persistence, and Durable Anti-tumor Activity in the Presence of Alloreactive T Cells |
All press releases naming this drug 6 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FT836 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07216105 ↗ |
| Modality | Cell therapy | “FT836, an Off-the-Shelf CAR T-Cell Therapy” NCT07216105 ↗ |
| Route | Intravenous | “FT836 drug product is administered as an intravenous infusion” NCT07216105 ↗ |